Glenmark Pharmaceuticals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	4,018	3,264	+23.1%
EBITDA	805	581	+38.6%
EBITDA margin	20.0%	17.8%	+2.3 pts
Profit before tax	643	95.6	+573.2%
Net profit	483	47.0	+927.9%
EPS	₹17.11	₹1.66	+930.7%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	4,018	3,771	3,901	6,047	3,264	3,256	3,388	3,434	3,244	3,063	2,507	3,207	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	65.8	189	44.5	201	26.4	11.7	31.1	39.4	31.5	773	45.4	1.7
	4,084	3,960	3,945	6,247	3,291	3,268	3,419	3,473	3,276	3,836	2,552	3,209
	601	731	775	723	732	795	746	774	686	754	658	916
	661	446	749	620	581	345	418	443	360	211	413	409
	−16.0	−5.2	−229	−78.4	−298	−50.6	−80.3	−147	64.3	30.4	−38.4	−127
	935	887	841	1,086	763	737	788	787	710	701	753	733
	54.0	42.6	41.4	66.5	58.2	66.7	52.3	48.5	39.6	149	134	121
	173	148	154	141	130	125	123	120	118	151	147	141
	1,033	948	894	1,337	906	870	915	975	835	862	930	814
	3,441	3,199	3,227	3,895	2,872	2,887	2,962	3,001	2,813	2,859	2,997	3,008
	805	763	870	2,360	581	561	600	602	588	504	−209	462
	632	615	715	2,218	451	436	477	482	470	353	−356	321
Profit
	643	761	718	2,353	419	381	456	473	462	978	−445	201
	0.0	−373	−184	−1,385	−323	−373	0.0	0.0	0.0	−447	−76.7	−325
	643	388	534	967	95.6	8.0	456	473	462	531	−521	−124
	211	−30.1	137	460	109	−3.5	103	136	147	1,058	−22.1	22.7
	−50.3	117	−6.5	−103	−60.7	7.1	5.2	−17.8	−24.8	711	−49.7	33.2
	161	86.4	131	357	48.6	3.6	108	118	122	1,769	−71.8	55.9
	483	301	403	610	47.0	4.4	348	354	340	−1,214	−331	−63.6
	483	301	403	610	47.0	4.4	348	354	340	−1,239	−450	−180
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.4	119	117
	40.4	189	20.0	104	101	258	−176	−22.4	5.5	75.9	4.7	−88.0
	523	490	423	715	148	262	172	332	346	−1,138	−326	−152
	483	−0.1	403	610	46.9	4.7	348	354	—	−1,218	−351	−81.9
	−0.1	301	0.0	0.1	0.1	−0.3	0.0	0.0	—	4.0	20.6	20.4
Per share
	₹17.11	₹10.68	₹14.29	₹21.63	₹1.66	₹0.16	₹12.33	₹12.55	₹12.06	−₹43.18	−₹12.45	−₹2.90
	₹17.11	₹10.68	₹14.28	₹21.62	₹1.66	₹0.16	₹12.33	₹12.55	₹12.06	−₹43.18	−₹12.45	−₹2.90
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.1	161	157
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	41.9	40.2
Other comprehensive income — detail
	40.4	189	20.0	104	101	258	—	—	—	—	—	—
	0.7	4.6	3.4	−18.3	0.9	−6.2	−0.5	−4.5	−0.7	−9.4	−3.5	−7.2
	0.2	3.6	1.1	−2.5	0.2	−2.0	—	—	—	—	—	—
	—	—	—	—	—	—	−0.2	−1.4	−0.3	−2.7	0.8	−3.0
	45.0	215	24.9	142	102	261	−164	−16.3	6.1	84.7	8.1	−76.2
	5.1	27.1	7.3	21.6	1.1	−0.9	—	—	—	—	—	—
	—	—	—	—	—	—	12.2	2.9	0.1	2.0	−0.9	7.5
	523	−0.1	423	715	148	262	171	332	—	−1,142	−346	—
	−0.1	490	0.0	0.1	0.1	−0.3	0.1	0.2	—	4.0	19.9	—
Per share — as-filed variants
	₹17.11	₹10.68	₹14.29	₹21.63	₹1.66	₹0.16	₹12.33	₹12.55	₹12.06	−₹44.04	−₹16.66	−₹7.11
	₹17.11	₹10.68	₹14.28	₹21.62	₹1.66	₹0.16	₹12.33	₹12.55	₹12.06	−₹44.04	−₹16.66	−₹7.11
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.86	₹4.21	₹4.21
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.86	₹4.21	₹4.21
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,773	2,598	2,606	4,782	2,249	2,167	2,303	2,364	2,134	2,067	1,474	2,010
	69.0%	68.9%	66.8%	79.1%	68.9%	66.6%	68.0%	68.8%	65.8%	67.5%	58.8%	62.7%
Adjusted (ex-exceptional items) — derived
	643	761	718	2,353	419	381	456	473	462	978	−445	201
	0.0	−373	−184	−1,385	−323	−373	0.0	0.0	0.0	−447	−76.7	−325
	483	591	542	1,484	206	209	348	354	340	−1,036	−265	262
	₹17.11	₹20.96	₹19.22	₹52.60	₹7.27	₹7.64	₹12.33	₹12.55	₹12.06	−₹36.82	−₹9.96	₹11.95

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLENMARK₹2,300.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDRREDDY LUPIN ALKEM BIOCON MANKIND LAURUSLABS FORTIS AUROPHARMAMcap ₹64,906 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	3,207.4	2,506.7	3,063.0	3,244.2	3,433.8	3,387.6	3,256.2	3,264.4	6,046.9	3,900.6	3,770.6	4,018.5
Other Income	1.7	45.4	773.2	31.5	39.4	31.1	11.7	26.4	200.6	44.5	189.1	65.8
Total Income	3,209.1	2,552.1	3,836.1	3,275.7	3,473.2	3,418.7	3,267.9	3,290.9	6,247.5	3,945.1	3,959.7	4,084.2
Expenses
+ Cost of Materials Consumed	915.8	657.5	754.3	685.8	774.4	746.4	794.8	732.5	722.5	775.3	731.2	601.1
+ Purchases of Stock-in-Trade	408.8	413.1	210.8	360.0	443.1	418.2	344.7	581.3	620.4	748.6	446.3	660.8
+ Changes in Inventories	-126.8	-38.4	30.4	64.3	-147.4	-80.3	-50.6	-298.2	-78.4	-228.8	-5.2	-16.0
+ Employee Benefit Expense	732.9	753.0	701.0	710.4	786.6	788.5	736.6	762.8	1,086.3	841.4	887.4	934.7
+ Finance Costs	121.5	134.3	148.6	39.6	48.5	52.3	66.7	58.2	66.5	41.4	42.6	54.0
+ Depreciation & Amortisation	141.5	147.1	151.3	117.8	120.3	122.7	125.2	129.9	141.2	154.4	147.9	173.2
+ Other Expenses	814.4	930.1	862.1	835.5	975.2	914.6	869.7	905.6	1,336.6	894.4	948.3	1,033.2
Total Expenses	3,008.0	2,996.8	2,858.5	2,813.3	3,000.6	2,962.4	2,887.1	2,872.1	3,895.0	3,226.7	3,198.5	3,440.9
EBITDA	462.3	-208.6	504.3	588.2	601.9	600.2	561.0	580.5	2,359.6	869.7	762.6	804.8
EBIT	320.8	-355.7	353.0	470.4	481.6	477.5	435.8	450.6	2,218.4	715.3	614.7	631.6
Profit
PBT before Exceptional Items	201.1	-444.7	977.6	462.3	472.6	456.3	380.8	418.8	2,352.5	718.3	761.2	643.4
+ Exceptional Items	-325.4	-76.7	-446.8	0.0	0.0	0.0	-372.8	-323.2	-1,385.1	-184.3	-373.4	0.0
Pretax Income	-124.4	-521.4	530.8	462.3	472.6	456.3	8.0	95.6	967.4	534.0	387.8	643.4
+ Current Tax	22.7	-22.1	1,058.2	146.9	135.9	103.1	-3.5	109.3	460.0	137.3	-30.1	210.8
+ Deferred Tax	33.2	-49.7	711.3	-24.8	-17.8	5.2	7.1	-60.7	-103.1	-6.5	116.6	-50.3
Tax Expense	55.9	-71.8	1,769.5	122.1	118.1	108.3	3.6	48.6	357.0	130.8	86.4	160.6
Net Income	-63.6	-330.8	-1,214.3	340.2	354.5	348.0	4.4	47.0	610.4	403.2	301.3	482.8
+ Net Income — Continuing Ops	-180.3	-449.6	-1,238.6	340.2	354.5	348.0	4.4	47.0	610.4	403.2	301.3	482.8
+ Net Income — Discontinued Ops	116.7	118.8	24.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	-88.0	4.7	75.9	5.5	-22.4	-176.5	257.6	101.3	104.5	20.0	188.6	40.4
Total Comprehensive Income	-151.6	-326.1	-1,138.4	345.7	332.1	171.6	262.0	148.3	714.9	423.2	489.9	523.3
Net Income to Common	-81.9	-351.4	-1,218.3	—	354.5	348.0	4.7	46.9	610.4	403.2	-0.1	482.9
Minority Interest	20.4	20.6	4.0	—	0.0	0.0	-0.3	0.1	0.1	0.0	301.4	-0.1
Per Share
Basic EPS	-2.90	-12.45	-43.18	12.06	12.55	12.33	0.16	1.66	21.63	14.29	10.68	17.11
Diluted EPS	-2.90	-12.45	-43.18	12.06	12.55	12.33	0.16	1.66	21.62	14.28	10.68	17.11
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	156.9	160.7	31.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Tax — Discontinued Operations	40.2	41.9	6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	257.6	101.3	104.5	20.0	188.6	40.4
+ Items NOT to be Reclassified to P&L	-7.2	-3.5	-9.4	-0.7	-4.5	-0.5	-6.2	0.9	-18.3	3.4	4.6	0.7
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-2.0	0.2	-2.5	1.1	3.6	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-3.0	0.8	-2.7	-0.3	-1.4	-0.2	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-76.2	8.1	84.7	6.1	-16.3	-163.9	261.0	101.8	141.9	24.9	214.7	45.0
+ Tax on Items to be Reclassified	—	—	—	—	—	—	-0.9	1.1	21.6	7.3	27.1	5.1
+ Tax on Items to be Reclassified — alt tag	7.5	-0.9	2.0	0.1	2.9	12.2	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	—	-346.0	-1,142.4	—	331.8	171.5	262.2	148.2	714.8	423.2	-0.1	523.4
Comprehensive Income — Non-controlling Interests	—	19.9	4.0	—	0.2	0.1	-0.3	0.1	0.1	0.0	490.0	-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	-7.11	-16.66	-44.04	12.06	12.55	12.33	0.16	1.66	21.63	14.29	10.68	17.11
Diluted EPS — Continuing Operations	-7.11	-16.66	-44.04	12.06	12.55	12.33	0.16	1.66	21.62	14.28	10.68	17.11
Basic EPS — Discontinued Operations	4.21	4.21	0.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	4.21	4.21	0.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,009.6	1,474.4	2,067.4	2,134.1	2,363.7	2,303.3	2,167.3	2,248.9	4,782.4	2,605.5	2,598.3	2,772.7
Gross Margin %	62.66	58.82	67.50	65.78	68.84	67.99	66.56	68.89	79.09	66.80	68.91	69.00
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	201.1	-444.7	977.6	462.3	472.6	456.3	380.8	418.8	2,352.5	718.3	761.2	643.4
− Exceptional Items (reconciliation)	-325.4	-76.7	-446.8	0.0	0.0	0.0	-372.8	-323.2	-1,385.1	-184.3	-373.4	0.0
Net Income Adj (tax-effected)	261.9	-264.7	-1,035.6	340.2	354.5	348.0	209.4	205.8	1,484.4	542.4	591.5	482.8
EPS Adj	11.95	-9.96	-36.82	12.06	12.55	12.33	7.64	7.27	52.60	19.22	20.96	17.11
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Glenmark Pharmaceuticals Q2 FY27 results date

Glenmark Pharmaceuticals (NSE: GLENMARK) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 23 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹483 crore, up 930.3% from ₹46.9 crore in Q1 FY26 and against a loss of ₹9.5 lakh in Q4 FY26. Revenue from operations was ₹4,018 crore, up 23.1% year on year and up 6.6% from the previous quarter.

Board-meeting notice filed: 23 October 2026
Q2 FY26 results (a year earlier): 14 November 2025
Q1 FY27 results (the latest): 31 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 23 Oct
Q1 FY27 net profit: ₹483 Cr+930.3% vs Q1 FY26loss ₹9.5 lakh in Q4 FY26
Q1 FY27 revenue: ₹4,018 Cr+23.1% vs Q1 FY26+6.6% vs Q4 FY26
Q1 FY27 operating margin: 15.7%+1.9 pts vs Q1 FY26−0.6 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹610 CrRevenue ₹6,047 Cr
Q1 FY27 EPS (basic): ₹17.11

Questions

When will Glenmark Pharmaceuticals announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 23 October 2026). Last year it reported Q2 FY26 on 14 November 2025.

What will Glenmark Pharmaceuticals' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹610 crore and revenue from operations ₹6,047 crore. The latest quarter, Q1 FY27, had a net profit of ₹483 crore and revenue of ₹4,018 crore.

What was Glenmark Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹16,983 crore in FY26 (April 2025–March 2026), up 27.5% from ₹13,322 crore in FY25. It was ₹11,813 crore in FY24 and ₹12,990 crore in FY23: up 30.7% over three years, 9.3% a year on average.

What were Glenmark Pharmaceuticals' Q1 FY27 results?

Consolidated net profit was ₹483 crore, up 930.3% from ₹46.9 crore in Q1 FY26 and against a loss of ₹9.5 lakh in Q4 FY26. Revenue from operations was ₹4,018 crore, up 23.1% year on year and up 6.6% from the previous quarter.

How has Glenmark Pharmaceuticals' profit changed over the last four quarters?

Net profit by quarter: a profit of ₹610 crore in Q2 FY26, a profit of ₹403 crore in Q3 FY26, a loss of ₹9.5 lakh in Q4 FY26 and a profit of ₹483 crore in Q1 FY27. That is a combined profit of ₹1,496 crore over the four quarters, up 98.5% from ₹754 crore in the four quarters before. Revenue from operations: ₹6,047 crore, ₹3,901 crore, ₹3,771 crore and ₹4,018 crore.

What was Glenmark Pharmaceuticals' net profit in FY26?

Consolidated net profit was ₹10 lakh in FY26 (April 2025–March 2026), down 100.0% from ₹1,047 crore in FY25. It was a loss of ₹1,502 crore in FY24 and a profit of ₹377 crore in FY23: down 100.0% over three years, an average fall of 93.6% a year.

Where do these Glenmark Pharmaceuticals figures come from?

From Glenmark Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.